Janssen/Alza fentanyl
Executive Summary
FDA has expressed concern over improper use of Duragesic first generation fentanyl patch product. Janssen is expected to issue a "Dear Doctor" letter to remind medical community of labeled indications. Among current label restrictions is a statement that the product is not recommended for treatment of post-op pain. As Janssen prepares to clarify current product usage, Alza reports to securities analysts on Jan. 13 that the two companies are in clinical trials with a fentanyl product using Alza's electrotransport technology. The new product "will allow a patient to titrate the level of required opioid input to alleviate severe pain through the use of a self-adhesive, disposable, transdermal system." The second generation product is designed for the acute pain market, Alza says...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: